| Literature DB >> 34564185 |
Giang Nam Pham1, Da Yeun Kang1, Min Ju Kim2, Se Jong Han2,3, Jun Hyuck Lee3,4, MinKyun Na1.
Abstract
Two undescribed rearranged cadinane-type sesquiterpenoids (1-2), named sinulaketol A-B, together with one new chlorinated steroid (3), one new gorgosterol (4), one known sesquiterpene (5), one known dibromoditerpene (6) and two known polyhydroxylated steroids (7-8) were isolated from the soft coral Sinularia brassica. The structures of these compounds were established by extensive spectroscopic analysis, including HRESIMS, 1D, and 2D NMR spectroscopy. Their absolute configurations were also determined by the ECD calculations and DP4+ probability analysis. Antileishmanial activity of compounds 1-8 was evaluated in vitro against the amastigote forms of Leishmania donovani, in which compounds 3, 6, and 7 inhibited the growth of L. donovani by 58.7, 74.3, 54.7%, respectively, at a concentration of 50 μM. Antimicrobial effect of the isolated compounds were also evaluated against Candida albicans, Staphylococcus aureus, and Escherichia coli. Compound 6, a brominated diterpene, exhibited antimicrobial effect against S. aureus.Entities:
Keywords: Sinularia brassica; antileishmanial activity; antimicrobial activity; sesquiterpenoids; steroids
Mesh:
Substances:
Year: 2021 PMID: 34564185 PMCID: PMC8466225 DOI: 10.3390/md19090523
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–8 isolated from the Sinularia brassica.
1H and 13C NMR data of compound 1.
| No | δH * ( | δC * | δH
# ( | δC # |
|---|---|---|---|---|
| 1 | 1.81 (br d, 11.0) | 51.0 | 1.55 (br d, 11.0) | 50.7 |
| 2 | - | 72.9 | - | 70.7 |
| 3 | 1.99 (m) | 39.7 | 1.80 (m) | 40.1 |
| 1.90 (ddd, 14.0, 9.6, 4.3) | 1.74 (m) | |||
| 4 | 2.75 (ddd, 15.3, 9.6, 4.7) | 35.4 | 2.52 (m) | 34.6 |
| 2.53 (ddd, 15.3, 8.9, 4.3) | 2.35 (ddd, 15.8, 6.3, 4.3) | |||
| 5 | - | 213.5 | - | 209 |
| 6 | - | 77.5 | - | 76.2 |
| 7 | 1.72 (m) | 47.9 | 1.77 (m) | 44.1 |
| 8 | 1.98 (m) | 22.8 | 1.88 (m) | 22.4 |
| 1.62 (ddt, 13.8, 4.4, 2.3) | 1.41 (ddd, 13.0, 4.3, 2.0) | |||
| 9 | 1.49 (m) | 31.2 | 1.35 (ddt, 11.9, 4.9, 2.4) | 31.2 |
| 1.30 (m) | 1.21 (m) | |||
| 10 | 2.12 (m) | 29.1 | 2.04 (m) | 28.5 |
| 11 | 1.76 (m) | 26.5 | 1.68 (m) | 26.1 |
| 12 | 0.95 (d, 6.3) | 22.5 | 0.90 (d, 6.5) | 22.7 |
| 13 | 0.72 (d, 6.5) | 23.8 | 0.66 (d, 6.8) | 23.3 |
| 14 | 1.16 (d, 6.5) | 22.7 | 1.06 (d, 6.5) | 22.6 |
| 15 | 1.43 (s) | 25.5 | 1.26 (s) | 23.1 |
| OH-2 | - | - | 4.14 (br s) | - |
| OH-6 | - | - | 4.79 (br s) | - |
* measured in CDCl3; # measured in DMSO-d.
Figure 2(a) Key COSY and HMBC correlations of 1 and 2. (b) and (c) MMFF-energy minimized structures and key NOE correlations of 1 and 2, respectively.
Figure 3Experimental and calculated ECD spectra of 1 and 2.
1H and 13C NMR data of compound 2.
| No | δH * ( | δC * | δH
# ( | δC # |
|---|---|---|---|---|
| 1 | 2.22 (d, 4.4) | 48.6 | 1.85 (m) | 48.5 |
| 2 | - | 71.9 | - | 70.0 |
| 3 | 2.01 (m) | 40.6 | 1.75 (m) | 40.7 |
| 1.90 (m) | 1.70 (m) | |||
| 4 | 2.66 (ddd, 18.2, 8.3, 4.5) | 35.9 | 2.52 (m) | 35.2 |
| 2.60 (m) | 2.33 (ddd, 18.1, 5.7, 3.0) | |||
| 5 | - | 215.3 | - | 210.3 |
| 6 | - | 79.8 | - | 78.0 |
| 7 | 1.59 (m) | 50.8 | 1.73 (m) | 46.5 |
| 8 | 2.16 (tt, 14.2, 4.2) | 19.4 | 2.06 (m) | 18.9 |
| 1.53 (m) | 1.36 (m) | |||
| 9 | 1.82 (m) | 30.2 | 1.76 (m) | 29.9 |
| 1.36 (dq, 13.6, 3.4) | 1.20 (m) | |||
| 10 | 2.44 (m) | 28.4 | 2.39 (m) | 27.7 |
| 11 | 1.80 (m) | 26.7 | 1.74 (m) | 26.4 |
| 12 | 0.96 (d, 6.6) | 22.3 | 0.90 (d, 6.0) | 22.8 |
| 13 | 0.71 (d, 6.7) | 24.2 | 0.64 (d, 6.2) | 23.7 |
| 14 | 1.31 (d, 7.3) | 18.5 | 1.25 (d, 7.2) | 19.0 |
| 15 | 1.50 (s) | 26.1 | 1.40 (s) | 24.9 |
| OH-2 | - | - | 4.37 (s) | - |
| OH-6 | - | - | 4.64 (d, 1.9) | - |
* measured in CDCl3; # measured in DMSO-d6.
Figure 4(a) Key COSY and HMBC correlations of 3. (b) MMFF-energy minimized structure and key NOE correlations of 3.
DP4+ probabilities for 3.
| Isomer 24 | Isomer 24 | |
|---|---|---|
| sDP4+ (H data) | 0.25% | 99.75% |
| sDP4+ (C data) | 12.83% | 87.17% |
| sDP4+ (all data) | 0.04% | 99.96% |
| uDP4+ (H data) | 0.39% | 99.61% |
| uDP4+ (C data) | 2.53% | 97.47% |
| uDP4+ (all data) | 0.01% | 99.99% |
| DP4+ (H data) | 0.00% | 100.00% |
| DP4+ (C data) | 0.38% | 99.62% |
| DP4+ (all data) | 0.00% | 100.00% |
Figure 5(a) Key COSY and HMBC correlations of 4. (b) MMFF-energy minimized structure and key NOE correlations of 4.
1H and 13C-NMR data of compound 3 and 4 in CDCl3.
| No | 3 | 4 | ||
|---|---|---|---|---|
| δH ( | δC | δH ( | δC | |
| 1 | 1.84 (m) | 36.8 | 1.69 (m) | 32.6 |
| 2 | 1.90 (m) | 28.2 | 1.92 (m) | 31.3 |
| 3 | 3.27 (ddd, 11.3, 9.4, 4.7) | 76.7 | 3.91 (tt, 11.3, 4.8) | 68.9 |
| 4 | 4.06 (dd, 9.4, 2.7) | 75.3 | 2.07 (dd, 12.7, 11.3) | 40.0 |
| 5 | - | 142.1 | - | 65.8 |
| 6 | 5.74 (dt, 2.1, 4.9) | 117.9 | 2.90 (d, 4.4) | 59.5 |
| 7 | 2.10 (m) | 31.6 | 1.92 (m) | 29.0 |
| 8 | 1.44 (m) | 31.7 | 1.36 (m) | 30.1 |
| 9 | 0.99 (m) | 50.6 | 1.25 (m) | 42.7 |
| 10 | - | 38.2 | - | 35.0 |
| 11 | 1.49 (m) | 21.0 | 1.38 (m) | 20.8 |
| 12 | 1.16 (m) | 39.8 | 1.13 (m) | 39.6 |
| 13 | - | 42.4 | - | 42.9 |
| 14 | 1.00 (m) | 56.8 | 0.96 (m) | 56.9 |
| 15 | 1.10 (m); 1.62 (m) | 24.4 | 1.00 (m); 1.58 (m) | 24.4 |
| 16 | 1.27 (m); 1.89 (m) | 28.4 | 1.28 (m); 2.00 (m) | 28.2 |
| 17 | 1.14 (m) | 55.8 | 1.20 (m) | 57.8 |
| 18 | 0.69 (s) | 12.0 | 0.59 (s) | 12.1 |
| 19 | 1.02 (s) | 20.4 | 1.06 (s) | 16.1 |
| 20 | 1.40 (m) | 36.3 | 0.98 (m) | 35.4 |
| 21 | 0.95 (overlap) | 18.9 | 0.97 (br s) | 21.2 |
| 22 | 1.42 (m) | 29.0 | 0.16(td, 8.6, 5.7) | 32.2 |
| 23 | 1.70 (m); 1.41 (m) | 31.1 | - | 25.9 |
| 24 | - | 75.4 | 0.23 (dq, 9.0, 6.9) | 50.9 |
| 25 | 1.95 (m) | 33.2 | 1.56 (m) | 32.2 |
| 26 | 0.93 (overlap) | 16.8 | 0.85 (d, 6.6) | 21.7 |
| 27 | 0.94 (overlap) | 17.2 | 0.94 (d, 6.7) | 22.3 |
| 28 | 3.56 (d, 11.2) | 51.7 | 0.93 (d, 6.9) | 15.6 |
| 29 | - | - | 0.89 (s) | 14.4 |
| 30 | - | - | −0.14 (dd, 5.9, 4.3) | 21.4 |
Antileishmanial and antimicrobial activity of compounds 1–8.
| Compound | Antileishmanial | Antimicrobial | |||
|---|---|---|---|---|---|
| Inhibition of Parasites (%) a | Cell Viability (%) b |
|
|
| |
| IC50 (μg/mL) | |||||
| 1 | −5.3 | 96.2 | NAc | NA | NA |
| 2 | 1.4 | 96.5 | NA | NA | NA |
| 3 | 58.7 | 88.8 | NA | NA | NA |
| 4 | −11.9 | 97.1 | NA | NA | NA |
| 5 | −12.3 | 97.0 | NA | NA | NA |
| 6 | 74.3 | 106.2 | NA | >104 | NA |
| 7 | 54.7 | 96.1 | NA | NA | NA |
| 8 | 39.0 | 92.7 | NA | NA | NA |
| kanamycin | NA | 13.5 | 1.50 ± 0.24 | ||
| nystatin | 0.93 ± 0.18 | NA | NA | ||
a Inhibition of a growth of L. donovani at 50 μM, b Cell viability of compounds in THP-1 cell at 50 μM, NA: Not active at 500 μg/mL.